Acadia pharmaceuticals reports first quarter 2022 financial results
San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad), today announced its financial results for the first quarter ended march 31, 2022. “nuplazid continued to deliver year over year growth in the first quarter of 2022,” said steve davis, chief executive officer. “in the near term, we are focused on preparing for the upcoming advisory committee meeting in connection with our resubmitted snda for pimavanserin in alzheimer’s disease psychosis. in addition, we have aligned with the fda on the contents of our upcoming nda submission for trofinetide in rett syndrome and continue to enroll patients in our ongoing phase 3 study evaluating pimavanserin for the negative symptoms of schizophrenia.” company highlights the u.s. food and drug administration (fda) advisory committee meeting is scheduled for june 17, 2022 to review the resubmission of the supplemental new drug application (snda) for pimavanserin for the treatment of hallucinations and delusions associated with alzheimer’s disease psychosis (adp). the fda is targeting an august 4, 2022 action date for the resubmitted snda for pimavanserin for the treatment of adp. trofinetide for the treatment of rett syndrome remains on track for an nda submission around mid-year 2022. late-breaker oral presentation on the efficacy and safety data from the phase 3 lavender study of trofinetide was presented at the 2022 american academy of neurology annual meeting (aan) on april 5, 2022. parag meswani joined acadia as senior vice president, trofinetide - rare disease franchise to lead the trofinetide commercial effort. in addition, holly valdiviez joined acadia as senior vice president, head of sales for nuplazid. parag and holly have joined acadia’s executive management committee. financial results revenue net sales of nuplazid (pimavanserin) were $115.5 million for the three months ended march 31, 2022, an increase of 8% as compared to $106.6 million reported for the three months ended march 31, 2021. research and development research and development expenses for the three months ended march 31, 2022 were $128.9 million, compared to $57.0 million for the same period of 2021. this increase was primarily due to expensing of the $60.0 million upfront payment made to stoke therapeutics under the license and collaboration agreement made in january 2022. selling, general and administrative selling, general and administrative expenses for the three months ended march 31, 2022 were $96.7 million, compared to $111.7 million for the same period of 2021. this decrease was primarily due to decreased advertising and promotional costs and decreased personnel expenses. net loss for the three months ended march 31, 2022, acadia reported a net loss of $113.1 million, or $0.70 per common share, compared to a net loss of $66.4 million, or $0.42 per common share, for the same period in 2021. this increase in net loss was primarily due to expensing of the $60.0 million upfront payment made to stoke therapeutics under the license and collaboration agreement made in january 2022. the net losses for the three months ended march 31, 2022 and 2021 included $15.0 million and $13.2 million, respectively, of non-cash stock-based compensation expense. cash and investments at march 31, 2022, acadia’s cash, cash equivalents, and investment securities totaled $446.0 million, compared to $520.7 million at december 31, 2021. 2022 financial guidance acadia is reiterating its previously provided guidance ranges: nuplazid net sales guidance of $510 to $560 million. gaap r&d guidance of $355 to $375 million, which includes approximately $25 million of stock-based compensation expense. gaap sg&a guidance of $360 to $380 million, which includes approximately $45 million of stock-based compensation expense. conference call and webcast information acadia management will review its first quarter financial results and operations via conference call and webcast today at 4:30 p.m. eastern time. the conference call may be accessed by dialing 855-638-4820 for participants in the united states or canada and 443-877-4067 for international callers (reference passcode 6989476). a telephone replay of the conference call may be accessed through may 19, 2022 by dialing 855-859-2056 for callers in the united states or canada and 404-537-3406 for international callers (reference passcode 6989476). the conference call also will be webcast live on acadia’s website, www.acadia-pharm.com under the investors section and will be archived there until june 1, 2022. about nuplazid® (pimavanserin) pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-ht2a receptors. these receptors are thought to play an important role in neuropsychiatric disorders. in vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including d2), histamine, muscarinic, or adrenergic receptors. pimavanserin was approved for the treatment of hallucinations and delusions associated with parkinson’s disease psychosis by the u.s. food and drug administration in april 2016 under the trade name nuplazid. nuplazid is not approved for alzheimer’s disease psychosis. in addition, acadia is developing pimavanserin in other neuropsychiatric conditions. about trofinetide trofinetide is an investigational drug. it is a novel synthetic analog of the amino‐terminal tripeptide of igf-1 designed to treat the core symptoms of rett syndrome by potentially reducing neuroinflammation and supporting synaptic function. trofinetide is thought to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of rett syndrome pathophysiology. in the central nervous system, igf-1 is produced by both of the major types of brain cells – neurons and glia. igf-1 in the brain is critical for both normal development and for response to injury and disease. trofinetide has been shown to inhibit the production of inflammatory cytokines, inhibit the overactivation of microglia and astrocytes, and increase the amount of available igf-1 that can bind to igf-1 receptors. trofinetide has been granted fast track status and orphan drug designation for rett syndrome and has also been granted rare pediatric disease (rpd) designation by the fda. about acadia pharmaceuticals acadia is advancing breakthroughs in neuroscience to elevate life. for more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. we developed and commercialized the first and only approved therapy for hallucinations and delusions associated with parkinson’s disease psychosis. our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and rett syndrome. our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. for more information, visit us at www.acadia-pharm.com and follow us on linkedin and twitter. forward-looking statements statements in this press release that are not strictly historical in nature are forward-looking statements. these statements include, but are not limited to, statements related to: the potential opportunity for future growth in sales of nuplazid; the timing of ongoing and future clinical studies for pimavanserin; the development and commercialization of trofinetide; and guidance for full-year 2022 nuplazid net sales for parkinson’s disease psychosis only and certain expense line items. these statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. actual events or results may differ materially from those projected in any of such statements due to various factors, including the uncertainty of future commercial sales and related items that would impact net sales during 2022, the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. for a discussion of these and other factors, please refer to acadia’s annual report on form 10-k for the year ended december 31, 2021 as well as acadia’s subsequent filings with the securities and exchange commission. you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. this caution is made under the safe harbor provisions of the private securities litigation reform act of 1995. all forward-looking statements are qualified in their entirety by this cautionary statement and acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. acadia pharmaceuticals inc. condensed consolidated statements of operations (in thousands, except per share amounts) (unaudited) three months ended march 31, 2022 2021 revenues product sales, net $ 115,468 $ 106,554 total revenues 115,468 106,554 operating expenses cost of product sales, license fees and royalties (1) 2,950 4,692 research and development (1) 128,855 56,973 selling, general and administrative (1) 96,679 111,661 total operating expenses 228,484 173,326 loss from operations (113,016 ) (66,772 ) interest income, net 105 200 other income 340 145 loss before income taxes (112,571 ) (66,427 ) income tax expense 485 21 net loss $ (113,056 ) $ (66,448 ) net loss per common share, basic and diluted $ (0.70 ) $ (0.42 ) weighted average common shares outstanding, basic and diluted 161,231 160,011 (1) includes the following stock-based compensation expense cost of product sales, license fees and royalties $ 323 $ 163 research and development $ 5,464 $ 4,830 selling, general and administrative $ 9,176 $ 8,191 acadia pharmaceuticals inc. condensed consolidated balance sheets (in thousands) march 31, 2022 december 31, 2021 (unaudited) assets cash, cash equivalents and investment securities $ 445,977 $ 520,706 accounts receivable, net 62,713 64,366 interest and other receivables 769 978 inventory 7,009 7,881 prepaid expenses 25,755 23,892 total current assets 542,223 617,823 property and equipment, net 7,531 8,047 operating lease right-of-use assets 58,186 58,268 restricted cash 5,770 5,770 long-term inventory 6,205 6,217 other assets 4,336 3,997 total assets $ 624,251 $ 700,122 liabilities and stockholders’ equity accounts payable $ 10,768 $ 6,876 accrued liabilities 108,835 89,192 total current liabilities 119,603 96,068 operating lease liabilities 55,478 56,126 other long-term liabilities 4,373 7,034 total liabilities 179,454 159,228 total stockholders’ equity 444,797 540,894 total liabilities and stockholders’ equity $ 624,251 $ 700,122
